Signaling pathways
-
BA5291 LadarixinSummary: Ladarixin (DF2156A free base) is an orally active, non-competitive alterative inhibitor. - BA5292 NBI-74330Summary: NBI-74330 is a potent antagonist that inhibits the specific binding of (I)CXCL10 and (I)CXCL11.
- BA5293 DanirixinSummary: Danirixin is a selective, reversible antagonist.
- BA5294 LY2510924Summary: LY2510924 is a potent, selective antagonist; prevents SDF-1 from binding CXCR4.
- BA5295 MSX-122Summary: MSX-122 is an orally available partial antagonist that inhibits interactions with values of approximately 10 nM.
- BA5296 CXCR2-IN-2Summary: CXCR2-IN-2 is a selective, blood-brain barrier-crossing, orally bioavailable antagonist (5.2nM/1nM in β-arrestin and Tango assays, respectively).
- BA5297 PentixaforSummary: Pentixafor is a targeted peptide.
- BA5298 CXCR2-IN-1Summary: CXCR2-IN-1 is an antagonist permeable to the central nervous system.
- BA5299 ACT-777991Summary: ACT-777991 is a selective, orally effective antagonist.
- BA5300 USL311Summary: USL311 is a potent and selective antagonist with anticancer properties.